Dew, one also has to consider that Nexavar sales numbers have been hurt by the exchange rate change. In contrast, sales numbers in China are likely to be helped in the future by a rise in Chinese currency.
Poorgradstudent, at a 10% quarter to quarter sales increase, Nexavar sales will double in China in TWO years not three. I am not sure why you don't think the increase can hold up. It is at a low level now, and will keep increasing, unless you think the market is close to saturation, which would be astonishing due to the endemic incidence of HepB and consequently HCC. AS jq1234 pointed out, overall sales increases for Nexavar don't reflect growth in HCC as Nexavar has been losing ground in RCC, but the decrease in the latter is becoming less significant to overall Nexavar sales.
One last thing about Kyprolis sales numbers is that in addition to the $19 million reported, there was another $5 million sold to distributors. It wasn't booked as revenue for Q5, but was deferred to Q4 since it was sent to clinics or hospitals. Therefore, One could argue that Q3 Kyprolis sales were $24 million in Q3. That is pretty impressive to me, and bode very well for future earnings. This doesn't even account for Regorafenib sales that will begin to accrue. If the short term traders want to take profits, it fine with me because ONXX future looks very bright.
News 
Market Data 
Discover 
AI
